Trials / Completed
CompletedNCT00997282
A Study of OPC-262 in Patients With Type 2 Diabetes
A Multicenter, Randomized, Double-blind, Placebo-controlled, 3-arms Parallel Group Comparative Study of OPC-262 in Patients With Type 2 Diabetes (Phase 2/3 Study)
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 255 (estimated)
- Sponsor
- Kyowa Kirin Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years – 74 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this clinical study is to evaluate the superiority of the efficacy of OPC-262 (2.5 mg, and 5 mg) to placebo in patients with type 2 diabetes after 24 week treatment in a double-blind fashion and to evaluate the safety of OPC-262 to placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | OPC-262 2.5 mg | orally administered once daily for 24 weeks |
| DRUG | OPC-262 5 mg | orally administered once daily for 24 weeks |
| DRUG | Placebo | orally administered once daily for 24 weeks |
Timeline
- Start date
- 2009-09-01
- Primary completion
- 2010-10-01
- Completion
- 2010-10-01
- First posted
- 2009-10-19
- Last updated
- 2014-01-08
Locations
7 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT00997282. Inclusion in this directory is not an endorsement.